An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, will participate in the 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021. Management is available for one-on-one meetings, and interested investors can contact their Craig-Hallum representative to schedule. DiaMedica’s lead candidate, DM199, is aimed at treating acute ischemic stroke and chronic kidney disease. The company has initiated the ReMEDy Phase 2/3 trial for acute ischemic stroke and is completing enrollment in the REDUX Phase 2 trial for chronic kidney disease.
Positive
None.
Negative
None.
MINNEAPOLIS--(BUSINESS WIRE)--
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will be participating in the 12th Annual Craig-Hallum Alpha Select Conference being held virtually on Tuesday, November 16, 2021. Management will be available to participate in one-on-one meetings. Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering serious diseases. Its lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD). Based on promising early clinical results, DiaMedica has initiated and commenced enrollment in its ReMEDy Phase 2/3 trial in the treatment of AIS and is completing enrollment in its REDUX Phase 2 trial for the treatment of certain rare and significant unmet causes of CKD. For more information visit our website at www.diamedica.com.
For Investor Inquiries:
Tim McCarthy Managing Director, LifeSci Advisors, LLC tim@lifesciadvisors.com
Source: DiaMedica Therapeutics Inc.
FAQ
When is DiaMedica participating in the Craig-Hallum Alpha Select Conference?
DiaMedica Therapeutics will participate in the Craig-Hallum Alpha Select Conference on November 16, 2021.
What is DiaMedica's lead candidate DM199?
DM199 is a recombinant form of the KLK1 protein, aimed at treating acute ischemic stroke and chronic kidney disease.
What trials is DiaMedica currently conducting?
DiaMedica is conducting the ReMEDy Phase 2/3 trial for acute ischemic stroke and is completing enrollment in the REDUX Phase 2 trial for chronic kidney disease.
How can investors schedule a meeting with DiaMedica's management?
Investors interested in meeting DiaMedica's management can contact their Craig-Hallum representative to arrange a meeting.
